Supernus Pharmaceuticals Inc. (SUPN)

$32.22

up-down-arrow $0.87 (2.78%)

As on 25-Apr-2025 16:00EDT

Supernus Pharmaceuticals Inc. (SUPN) Share Price

High:loading Low:loading Return: loading

Max:loading Min:loading Median:loading

Max:loading Min:loading Median:loading

loading...
loading...
loading...
loading...

Stock Range

Today’s Range

Low: 31.16 High: 32.36

52 Week Range

Low: 25.53 High: 40.28

Liquidityliquidity High

Low Moderate High

Fundamentals

  • Market capMarket cap information

    $1,798 Mln

  • P/E RatioP/E Ratio information

    24.41

  • P/B RatioP/B Ratio information

    1.74

  • Industry P/EIndustry P/E information

    --

  • Debt to EquityDebt to Equity information

    0.03

  • ROEROE information

    0.08 %

  • ROCEROCE information

    7.27 %

  • Div. YieldDiv. Yield information

    0 %

  • Book ValueBook Value information

    18.51

  • EPSEPS information

    1.32

10 Years Aggregate

CFO

$986.86 Mln

EBITDA

$1,107.79 Mln

Net Profit

$648.84 Mln

Performance

YTD
1 Month
3 Months
1 Year
3 Years
5 Years
10 Years
Supernus Pharmaceuticals (SUPN)
-10.90 -1.47 -16.42 6.48 3.01 11.20 8.88
BSE Sensex*
2.49 3.34 6.41 8.77 12.17 20.37 11.43
S&P Small-Cap 600#
-5.82 -5.34 -13.73 -6.30 5.30 2.98 5.53
As on 25-Apr-2025  |  *As on 28-Apr-2025  |  #As on 26-Oct-2023
2024
2023
2022
2021
2020
2019
2018
Supernus Pharmaceuticals (SUPN)
24.72 -18.87 22.33 15.90 6.07 -28.60 -16.55
S&P Small-Cap 600
7.01 13.89 -17.42 25.27 9.57 20.86 -9.70
BSE Sensex
8.10 18.74 4.44 21.99 15.75 14.38 5.87

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

Detailed View
loading...

*All values are in ($ Mln)

loading...

*All values are in ($ Mln)

loading...

*All values are in ($ Mln)

Key Ratios

View All
loading...

loading...

loading...

3Y Avg -- 5Y Avg -- TTM --

loading...

P/E Ratio

--

--Min --Median --Max

loading...

P/B Ratio

--

--Min --Median --Max

loading...

Earnings Yield (%)

--

Earnings Yield (%) = EBIT / Enterprise value

PEG Ratio

--

Price = Price / Earnings to growth ratio

loading...

loading...

loading...

Peer

View All
Company
Price ($) Market Cap ($ Mln) P/E Ratio ROE
36.31 6,904.81 -- 38.11
71.71 7,574.08 58.3 23.56
59.16 11,448.88 394.4 0.76
8.13 9,704.70 -- -3.24

Shareholding Pattern

Detailed Holdings
loading...
BLAHBLAH

About The Company

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes products for the treatment of central nervous system (CNS) diseases in the United States. The company offers Qelbree, a non-stimulant indicated for the treatment...  of attention-deficit hyperactivity disorder (ADHD); GOCOVRI for the treatment of dyskinesia and levodopa/carbidopa in patients with Parkinson's Disease (PD); Oxtellar XR, an extended-release oxcarbazepine product indicated for the monotherapy treatment of partial onset epilepsy seizures; and APOKYN for the acute and intermittent treatment of hypomobility or off episodes in patients with advanced PD. It also provides Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; XADAGO for the treatment of levodopa/carbidopa in patients with PD experiencing off episodes; and MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and chronic sialorrhea. In addition, the company develops ONAPGO, which received FDA approval, for the treatment of motor fluctuations in adults with advanced PD; SPN-817, a first-in-class selective acetylcholinesterase inhibitor, which is in Phase 2 clinical trial, for the treatment of epilepsy, partial seizures, Dravet syndrome, and Lennox-Gaustaut syndrome; SPN-820, a small molecule in Phase 2 clinical trial for treating resistant depression; SPN-443, a stimulant in Phase 1 trial for the treatment of ADHD/CNS; and SPN-446, a preclinical product for CNS. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. It has a development agreement with Navitor Inc. for the conduct of Phase 2 clinical program of SPN-820. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is based in Rockville, Maryland.  Read more

  • Founder, President, CEO, Secretary & Director

    Mr. Jack A. Khattar

  • Founder, President, CEO, Secretary & Director

    Mr. Jack A. Khattar M.B.A.

  • Headquarters

    Rockville, MD

  • Website

    https://www.supernus.com

Edit peer-selector-edit
loading...
loading...

FAQs for Supernus Pharmaceuticals Inc. (SUPN)

The total asset value of Supernus Pharmaceuticals Inc (SUPN) stood at $ 1,368 Mln as on 31-Dec-24

The share price of Supernus Pharmaceuticals Inc (SUPN) is $32.22 (NASDAQ) as of 25-Apr-2025 16:00 EDT. Supernus Pharmaceuticals Inc (SUPN) has given a return of 3.01% in the last 3 years.

Supernus Pharmaceuticals Inc (SUPN) has a market capitalisation of $ 1,798 Mln as on 25-Apr-2025. As per Value Research classification, it is a Small Cap company.

The P/E ratio of Supernus Pharmaceuticals Inc (SUPN) is 24.41 times as on 25-Apr-2025.

Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Supernus Pharmaceuticals Inc (SUPN) and enter the required number of quantities and click on buy to purchase the shares of Supernus Pharmaceuticals Inc (SUPN).

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes products for the treatment of central nervous system (CNS) diseases in the United States. The company offers Qelbree, a non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD); GOCOVRI for the treatment of dyskinesia and levodopa/carbidopa in patients with Parkinson's Disease (PD); Oxtellar XR, an extended-release oxcarbazepine product indicated for the monotherapy treatment of partial onset epilepsy seizures; and APOKYN for the acute and intermittent treatment of hypomobility or off episodes in patients with advanced PD. It also provides Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; XADAGO for the treatment of levodopa/carbidopa in patients with PD experiencing off episodes; and MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and chronic sialorrhea. In addition, the company develops ONAPGO, which received FDA approval, for the treatment of motor fluctuations in adults with advanced PD; SPN-817, a first-in-class selective acetylcholinesterase inhibitor, which is in Phase 2 clinical trial, for the treatment of epilepsy, partial seizures, Dravet syndrome, and Lennox-Gaustaut syndrome; SPN-820, a small molecule in Phase 2 clinical trial for treating resistant depression; SPN-443, a stimulant in Phase 1 trial for the treatment of ADHD/CNS; and SPN-446, a preclinical product for CNS. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. It has a development agreement with Navitor Inc. for the conduct of Phase 2 clinical program of SPN-820. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is based in Rockville, Maryland.

The CEO & director of Mr. Jack A. Khattar. is Supernus Pharmaceuticals Inc (SUPN), and CFO & Sr. VP is Mr. Jack A. Khattar M.B.A..

There is no promoter pledging in Supernus Pharmaceuticals Inc (SUPN).

Supernus Pharmaceuticals Inc. (SUPN) Ratios
Return on equity(%)
7.55
Operating margin(%)
14.79
Net Margin(%)
11.16
Dividend yield(%)
--

No, TTM profit after tax of Supernus Pharmaceuticals Inc (SUPN) was $0 Mln.